Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
11.30
-0.08 (-0.70%)
At close: Mar 9, 2026, 4:00 PM EDT
11.53
+0.23 (2.04%)
After-hours: Mar 9, 2026, 4:10 PM EDT
Daxor Revenue
In the year 2025, Daxor had annual revenue of $26.69K, down -77.71%. Daxor had revenue of $18.35K in the half year ending June 30, 2025, a decrease of -77.34%.
Revenue (ttm)
$26.69K
Revenue Growth
-77.71%
P/S Ratio
2,492.42
Revenue / Employee
$593
Employees
45
Market Cap
65.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.69K | -93.03K | -77.71% |
| Dec 31, 2024 | 119.71K | -43.71K | -26.75% |
| Dec 31, 2023 | 163.42K | -68.22K | -29.45% |
| Dec 31, 2022 | 231.64K | -46.45K | -16.70% |
| Dec 31, 2021 | 278.09K | 13.65K | 5.16% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanara MedTech | 101.88M |
| Harvard Bioscience | 87.37M |
| Pro-Dex | 72.10M |
| Precision Optics Corporation | 24.42M |
| Nephros | 17.93M |
| Ekso Bionics Holdings | 12.80M |
| Nyxoah | 6.62M |
| Femasys | 2.06M |
DXR News
- 12 hours ago - Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 - GlobeNewsWire
- 6 days ago - Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share - GlobeNewsWire
- 13 days ago - Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee - GlobeNewsWire
- 6 weeks ago - Daxor Corporation Announces $9 Million Registered Direct Offering - GlobeNewsWire
- 3 months ago - Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer - GlobeNewsWire
- 4 months ago - Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit - GlobeNewsWire
- 5 months ago - Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA - GlobeNewsWire
- 5 months ago - Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting - GlobeNewsWire